Skip to main content
Premium Trial:

Request an Annual Quote

Takara Bio to Offer Pathogenica HAI Detection Kit in Japan

NEW YORK (GenomeWeb News) – Takara Bio said Monday that it has signed an agreement to offer Pathogenica's HAI BioDetection Kit in Japan as part of its sequencing services.

The sequencing-based kit enables identification of hospital acquired infections with a turnaround of less than 12 hours. According to Takara, the kit identifies what species are present in a sample and provides sequence data, including strain identity and resistance genes. Specifically, it can detect 12 bacteria commonly associated with HAIs and 15 resistance gene families in a single assay, and it can process 12 samples per sequencing run.

Shiga, Japan-based Takara Bio noted that the Pathogenica HAI BioDetection Kit is for research use only.

The firm also offers sequencing services through its Dragon Genomics Center.

Financial and other terms of the agreement were not disclosed.

Earlier this year Pathogenica signed an agreement with Life Technologies to distribute the test in Japan on the Ion Torrent platform.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more